Alethia Young
Stock Analyst at Cantor Fitzgerald
(2.93)
# 1,407
Out of 5,129 analysts
137
Total ratings
53.64%
Success rate
31.05%
Average return
Main Sectors:
Stocks Rated by Alethia Young
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $21.36 | - | 5 | Jul 5, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | n/a | $61.55 | - | 5 | Jun 20, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $800 → $850 | $778.97 | +9.12% | 9 | Oct 16, 2023 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | $18 | $2.48 | +625.81% | 6 | Sep 12, 2023 | |
| CRIS Curis | Reiterates: Overweight | $60 | $1.08 | +5,455.56% | 3 | Sep 7, 2023 | |
| ELDN Eledon Pharmaceuticals | Reiterates: Overweight | $9 | $2.02 | +345.54% | 2 | Aug 22, 2023 | |
| VSTM Verastem | Reiterates: Overweight | $34 | $6.34 | +436.28% | 2 | Jul 6, 2023 | |
| BIIB Biogen | Maintains: Neutral | $427 → $327 | $191.20 | +71.03% | 7 | Oct 15, 2021 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $408 → $568 | $57.72 | +884.06% | 2 | Jun 14, 2021 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $285 → $281 | $461.24 | -39.08% | 5 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $1.55 | +416.13% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $98 | $1.17 | +8,276.07% | 3 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $295 | $366.58 | -19.53% | 9 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $84 → $86 | $155.80 | -44.80% | 3 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $48 | $28.82 | +66.55% | 4 | Oct 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $5.53 | +442.99% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $72 | $27.71 | +159.83% | 8 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $5 | $1.84 | +171.74% | 5 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $83 → $100 | $98.84 | +1.17% | 6 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $185 → $201 | $221.49 | -9.25% | 6 | Apr 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $86 → $85 | $70.92 | +19.85% | 5 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $32 | $14.51 | +120.54% | 1 | Mar 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $211 → $217 | $17.96 | +1,108.24% | 12 | Feb 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $48 | $55.25 | -13.12% | 4 | Oct 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $18.30 | - | 3 | Mar 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $151 → $154 | $322.28 | -52.22% | 5 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $113 → $116 | $60.31 | +92.34% | 2 | Mar 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $147 → $106 | $6.64 | +1,496.39% | 8 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $28 | $12.00 | +133.33% | 1 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $82 | $212.79 | -61.46% | 2 | Sep 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | n/a | $475.85 | - | 1 | Mar 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.03 | - | 1 | Oct 18, 2016 |
Arcus Biosciences
Jul 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $21.36
Upside: -
Arrowhead Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $61.55
Upside: -
Regeneron Pharmaceuticals
Oct 16, 2023
Maintains: Neutral
Price Target: $800 → $850
Current: $778.97
Upside: +9.12%
ALX Oncology Holdings
Sep 12, 2023
Reiterates: Overweight
Price Target: $18
Current: $2.48
Upside: +625.81%
Curis
Sep 7, 2023
Reiterates: Overweight
Price Target: $60
Current: $1.08
Upside: +5,455.56%
Eledon Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $9
Current: $2.02
Upside: +345.54%
Verastem
Jul 6, 2023
Reiterates: Overweight
Price Target: $34
Current: $6.34
Upside: +436.28%
Biogen
Oct 15, 2021
Maintains: Neutral
Price Target: $427 → $327
Current: $191.20
Upside: +71.03%
RAPT Therapeutics
Jun 14, 2021
Maintains: Overweight
Price Target: $408 → $568
Current: $57.72
Upside: +884.06%
Vertex Pharmaceuticals
Jun 11, 2021
Maintains: Overweight
Price Target: $285 → $281
Current: $461.24
Upside: -39.08%
Mar 8, 2021
Initiates: Overweight
Price Target: $8
Current: $1.55
Upside: +416.13%
Feb 25, 2021
Maintains: Overweight
Price Target: $86 → $98
Current: $1.17
Upside: +8,276.07%
Feb 3, 2021
Maintains: Overweight
Price Target: $280 → $295
Current: $366.58
Upside: -19.53%
Oct 29, 2020
Reiterates: Overweight
Price Target: $84 → $86
Current: $155.80
Upside: -44.80%
Oct 28, 2020
Maintains: Overweight
Price Target: $30 → $48
Current: $28.82
Upside: +66.55%
Oct 12, 2020
Initiates: Overweight
Price Target: $30
Current: $5.53
Upside: +442.99%
Jul 31, 2020
Maintains: Overweight
Price Target: $70 → $72
Current: $27.71
Upside: +159.83%
Jun 2, 2020
Assumes: Overweight
Price Target: $5
Current: $1.84
Upside: +171.74%
May 19, 2020
Maintains: Neutral
Price Target: $83 → $100
Current: $98.84
Upside: +1.17%
Apr 20, 2020
Reiterates: Overweight
Price Target: $185 → $201
Current: $221.49
Upside: -9.25%
Apr 8, 2020
Reiterates: Overweight
Price Target: $86 → $85
Current: $70.92
Upside: +19.85%
Mar 6, 2020
Maintains: Overweight
Price Target: $30 → $32
Current: $14.51
Upside: +120.54%
Feb 27, 2020
Reiterates: Overweight
Price Target: $211 → $217
Current: $17.96
Upside: +1,108.24%
Oct 3, 2019
Maintains: Neutral
Price Target: $75 → $48
Current: $55.25
Upside: -13.12%
Mar 22, 2018
Downgrades: Underperform
Price Target: n/a
Current: $18.30
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $151 → $154
Current: $322.28
Upside: -52.22%
Mar 2, 2018
Maintains: Outperform
Price Target: $113 → $116
Current: $60.31
Upside: +92.34%
Jan 24, 2018
Maintains: Outperform
Price Target: $147 → $106
Current: $6.64
Upside: +1,496.39%
Nov 3, 2017
Maintains: Outperform
Price Target: $24 → $28
Current: $12.00
Upside: +133.33%
Sep 27, 2017
Maintains: Neutral
Price Target: $85 → $82
Current: $212.79
Upside: -61.46%
Mar 16, 2017
Initiates: Underperform
Price Target: n/a
Current: $475.85
Upside: -
Oct 18, 2016
Initiates: Outperform
Price Target: n/a
Current: $3.03
Upside: -